Taika Capital LP Buys New Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Taika Capital LP bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 36,775 shares of the company’s stock, valued at approximately $1,785,000. Amphastar Pharmaceuticals comprises about 1.3% of Taika Capital LP’s holdings, making the stock its 25th largest position. Taika Capital LP owned about 0.08% of Amphastar Pharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Aurora Investment Counsel lifted its holdings in Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock worth $2,654,000 after acquiring an additional 232 shares during the period. GAMMA Investing LLC lifted its holdings in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in Amphastar Pharmaceuticals by 2.5% during the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock worth $452,000 after acquiring an additional 275 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after acquiring an additional 301 shares during the period. Finally, Blue Trust Inc. lifted its holdings in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on AMPH. Wells Fargo & Company began coverage on Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price on the stock. StockNews.com lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Piper Sandler lowered their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $60.33.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $43.60 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The business has a 50-day simple moving average of $47.59 and a 200 day simple moving average of $44.59. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of 14.53, a PEG ratio of 0.89 and a beta of 0.78.

Insider Transactions at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 7,426 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now owns 94,103 shares of the company’s stock, valued at approximately $4,898,061.15. The trade was a 7.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at approximately $3,900,522.90. This trade represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 24,533 shares of company stock worth $1,238,842. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.